Quantification of Biomarker Proteins Using Reverse-Phase Protein Arrays
Quantification of Biomarker Proteins Using Reverse-Phase Protein Arrays
复制标题
使用反相蛋白质阵列对生物标志物蛋白质进行定量
DOI：
10.1002/prca.201900120
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Yamada T
中科院分区：
文献类型：
--
作者：
中村裕人，佐藤紫乃;樋浦諭志;高山純一;村山明宏;清水耕介;Yamada T
预计基于抗体的蛋白质组学将很快在生物标志物和治疗靶点的发现和验证中占据关键地位。反相蛋白质阵列（RPPA）是一种基于抗体的蛋白质组学方法，可以定量大量蛋白质样品中多种后修饰蛋白质（如已磷酸化的蛋白质）的表达。RPPA是高度敏感的，只需要非常小的蛋白质样品。这一特点与大型抗体库相结合，使RPPA成为临床蛋白质组学的理想选择，同时它也是一种可扩展的多重检测方法。在蛋白质组学临床应用第14卷第1期中，Suzuki及其同事首次报告了一项比较RPPA和免疫组织化学定量用于弥漫性大B-细胞淋巴瘤亚型分型的7种生物标志物蛋白的研究。多种生物标志物的这种组合可能提高诊断准确性，并可用于这种异质性疾病的精确分类。
It is expected that antibody‐based proteomics will soon occupy a pivotal position in the discovery and validation of biomarkers and therapeutic targets. The reverse‐phase protein array (RPPA) is an antibody‐based proteomic method that can quantify the expression of multiple posttranslationally modified proteins (such as those that have been phosphorylated) across a large number of protein samples. RPPA is highly sensitive and requires only very small protein samples. This feature, in combination with large antibody libraries, makes RPPA ideal for clinical proteomics, as well as the fact that it is an expandable multiplex assay. In Volume 14, Issue 1 ofProteomics Clinical Applications, Suzuki and colleagues report for the first time a study comparing RPPA and immunohistochemistry for quantification of seven biomarker proteins used for subtyping of diffuse large B‐cell lymphoma. Such combination of multiple biomarkers is likely to increase diagnostic accuracy and can be used for precise classification of this heterogeneous disease.